BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27984757)

  • 21. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
    da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
    Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis.
    Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Torrado-Santiago S; Torrado JJ
    J Drug Target; 2004; 12(7):453-60. PubMed ID: 15621670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of a nitric-oxide response during the course of Leishmania infantum infection in the golden hamster (Mesocricetus auratus), with or without treatment with liposomal amphotericin B.
    Bories C; Coffin C; Mathieu D; Bories PN; Scherman E; Rivollet D; Deniau M
    Ann Trop Med Parasitol; 1998 Sep; 92(6):685-92. PubMed ID: 9924547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation.
    Rama Iñiguez S; Dea-Ayuela MA; Sanchez-Brunete JA; Torrado JJ; Alunda JM; Bolas-Fernández F
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1195-201. PubMed ID: 16569829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
    Berman JD; Hanson WL; Chapman WL; Alving CR; Lopez-Berestein G
    Antimicrob Agents Chemother; 1986 Dec; 30(6):847-51. PubMed ID: 3813512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis.
    Jesus JA; Fragoso da Silva TN; Yamamoto ES; G Lago JH; Dalastra Laurenti M; Passero LFD
    Pathogens; 2020 Oct; 9(10):. PubMed ID: 33092305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection mediated by chemokine CXCL10 in BALB/c mice infected by Leishmania infantum.
    Figueiredo WME; Viana SM; Alves DT; Guerra PV; Coêlho ZCB; Barbosa HS; Teixeira MJ
    Mem Inst Oswaldo Cruz; 2017 Aug; 112(8):561-568. PubMed ID: 28767981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential role of zinc in the visceromegaly regression and recovery of hematological parameters during treatment of visceral leishmaniasis in children from an endemic area.
    Carbone DCB; Zanoni LZG; Cônsolo FZ; Sanches SC; Reis VQD; Muller KTC; Carvalho CME; Silva MC
    Rev Inst Med Trop Sao Paulo; 2018; 60():e50. PubMed ID: 30231161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antileishmanial effect of cisplatin against murine visceral leishmaniasis.
    Kaur S; Sachdeva H; Dhuria S; Sharma M; Kaur T
    Parasitol Int; 2010 Mar; 59(1):62-9. PubMed ID: 19853668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
    Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is Related to Programed Cell Death and Presents Therapeutic Potential in Experimental Cutaneous Leishmaniasis.
    Yamamoto ES; Campos BL; Jesus JA; Laurenti MD; Ribeiro SP; Kallás EG; Rafael-Fernandes M; Santos-Gomes G; Silva MS; Sessa DP; Lago JH; Levy D; Passero LF
    PLoS One; 2015; 10(12):e0144946. PubMed ID: 26674781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-leishmanial activity of a new formulation of amphotericin B.
    Dea-Ayuela MA; Rama-Iñiguez S; Sánchez-Brunete JA; Torrado JJ; Alunda JM; Bolás-Fernández F
    Trop Med Int Health; 2004 Sep; 9(9):981-90. PubMed ID: 15361111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.
    Collier MA; Peine KJ; Gautam S; Oghumu S; Varikuti S; Borteh H; Papenfuss TL; Sataoskar AR; Bachelder EM; Ainslie KM
    Int J Pharm; 2016 Feb; 499(1-2):186-194. PubMed ID: 26768723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.
    Murray HW; Brooks EB; DeVecchio JL; Heinzel FP
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2513-7. PubMed ID: 12878513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.